# ExSeed Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exseed-health

- Industry: Medical Devices & Equipment
- Headquarters: London, UK
- Website: www.exseedhealth.com
- Total disclosed funding: $4.4M
- Latest round: Seed (Dec 8, 2021)
- Investors on record: 4

## About

Based in London, UK, and founded in 2017 by CEO Morten G. Ulsted, Daniel Gewecke Daugaard, and Emil Andersen, ExSeed Health Limited, a.k.a. ExSeed operates as a health-tech company that provides an online healthcare service along with fertility medicine and kit for both men and women. In February 2022, ExSeed Health Limited raised GBP 2.5 million in seed funding led by Ascension Ventures, with participation from R42, Hambro Perks, and Trifork A/S.

ExSeed provides a sperm test kit built on fertility technology to track sperm volume, concentration, and motility for home use. The company also offers fertility supplements to improve sperm count, DNA quality, sperm motility, and testosterone levels. In addition, the firm offers a female fertility tracker kit that tracks fertility hormone levels through artificial intelligence ovulation and cycle prediction. ExSeeds other healthcare products include a refill kit, couple’s home testing pack, replacement test wands, cookbook, fertility guide, boot camp, and a mobile application for both android and iOS users.

The company generates revenue from sales of its products through its e-commerce platform.

ExSeed plans to use its proceeds from February 2022 funding to tackle rising male infertility and expand its business in Europe.

## Funding rounds

- Seed, Dec 8, 2021, $3.3M — Ascension Ventures, Trifork A/S, Salica Investments, R42
- Seed, Feb 20, 2020, $1M — Salica Investments

## Investors

- Salica Investments (https://capitalatlas.ai/funds/salica-investments) — Seed
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Seed
- Trifork A/S — Seed
- R42 (https://capitalatlas.ai/funds/r42) — Seed